Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Citi
Deloitte
Johnson and Johnson
QuintilesIMS
Covington
Farmers Insurance
Baxter
Julphar
Cerilliant

Generated: October 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,337,886

« Back to Dashboard

Claims for Patent: 8,337,886

Title:Pellet formulation for the treatment of the intestinal tract
Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s): Otterbeck; Norbert (Uberlingen, DE)
Assignee: Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:12/236,157
Patent Claims: 1. A controlled release pellet formulation for treatment of the intestinal tract, said formulation comprising a core comprising: 1) a homogeneously dispersed pharmaceutically active compound in a non gel-forming polymer matrix and 2) an enteric coating, wherein the non gel-forming polymer matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluid made by the process comprising: mixing the pharmaceutically active compound and the non gel-forming polymer matrix; scattering in a pharmaceutically tolerable additive; and extruding a moist mass of the matrix-forming polymer and the active compound.

2. The controlled release pharmaceutical pellet formulation of claim 1, wherein the process further comprises applying an enteric coating to a pellet made from the moist mass.

3. The controlled release pharmaceutical pellet formulation of claim 1, wherein the enteric coating comprises a methacrylic acid containing copolymer or methylhydroxypropyl cellulose phthalate.

4. The controlled release pharmaceutical pellet formulation of claim 3, wherein the methacrylic acid containing copolymer comprises co-poly(methacrylic acid, methyl methacrylate), wherein the co-polymer comprises free carboxylic acid functional groups.

5. The controlled release pharmaceutical pellet formulation of claim 1, wherein the process further comprises cutting the moist mass into pieces.

6. The controlled release pharmaceutical pellet formulation of claim 5, wherein the pieces are about 1 mm long.

7. The controlled release pharmaceutical pellet formulation of claim 5, wherein the process further comprises rounding the pieces in a spheronizer.

8. The controlled release pharmaceutical pellet formulation of claim 7, wherein the process further comprises drying the pieces.

9. The controlled release pharmaceutical pellet formulation of claim 8, wherein the pieces are dried at about 60.degree. C.

10. The controlled release pharmaceutical pellet formulation of claim 8, wherein the process further comprises: dissolving poly(methacrylic acid, methylmethacrylate) 1:1 in an ethanol/water mixture; suspending triethyl citrate, talc, titanium dioxide and magnesium stearate in the mixture; and coating the pieces with the suspended mixture.

11. The controlled release pharmaceutical pellet formulation of claim 1, wherein the matrix-forming polymer is selected from the group consisting of poly(ethyl acrylate, methyl methacrylate) and poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride).

12. The controlled release pharmaceutical pellet formulation of claim 1, wherein the non gel-forming polymer matrix makes up at least 1% by weight of the total weight of the core.

13. The controlled release pharmaceutical pellet formulation of claim 1, wherein the pharmaceutically active compound comprises 5-aminosalicylic acid, balsalazide, sulfasalazine or a pharmaceutically acceptable salt thereof.

14. The controlled release pharmaceutical pellet formulation of claim 1, wherein the pharmaceutical pellet formulation is used for the treatment of recurrence of inflammatory intestinal disorders, formation of polyps, intestinal cancer, colorectal polyps or colorectal cancer.

15. The controlled release pharmaceutical pellet formulation of claim 14, wherein the inflammatory intestinal disorders comprise Crohn's disease or ulcerative colitis.

16. The controlled release pharmaceutical pellet formulation of claim 1, wherein the pharmaceutical pellet formulation is used for the maintenance of remission of ulcerative colitis.

17. The controlled release pharmaceutical pellet formulation of claim 1, wherein the pellet formulation further comprises pharmaceutically tolerable additives.

18. The controlled release pharmaceutical pellet formulation of claim 1, wherein the pellets of the formulation are about 0.1 mm to about 3 mm in size.

19. A controlled release pellet formulation for treatment of the intestinal tract, said formulation comprising: 1) a core comprising a homogeneously dispersed pharmaceutically active compound in a non gel-forming polymer matrix and 2) an enteric coating, wherein the non gel-forming polymer matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluids, and wherein the non gel-forming polymer matrix makes up at least 1% by weight of the total weight of the core, and wherein the matrix-forming polymer is selected from the group consisting of poly(ethyl acrylate, methyl methacrylate) and poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride).

20. The controlled release pharmaceutical pellet formulation of claim 19, wherein the pharmaceutically active compound comprises 5-aminosalicylic acid, balsalazide, sulfasalazine or a pharmaceutically acceptable salt thereof.

21. The controlled release pharmaceutical pellet formulation of claim 19, wherein the pharmaceutical pellet formulation is contained in capsules.

22. The controlled release pharmaceutical pellet formulation of claim 19, wherein the pharmaceutical pellet formulation is contained in sachets.

23. The controlled release pharmaceutical pellet formulation of claim 19, wherein the pharmaceutical pellet formulation is used for the treatment of recurrence of inflammatory intestinal disorders, formation of polyps, intestinal cancer, colorectal polyps or colorectal cancer.

24. The controlled release pharmaceutical pellet formulation of claim 23, wherein the inflammatory intestinal disorders comprise Crohn's disease or ulcerative colitis.

25. The controlled release pharmaceutical pellet formulation of claim 19, wherein the pharmaceutical pellet formulation is used for the maintenance of remission of ulcerative colitis.

26. The controlled release pharmaceutical pellet formulation of claim 19, wherein the pellet formulation further comprises pharmaceutically tolerable additives.

27. The controlled release pharmaceutical pellet formulation of claim 19, wherein the pellets of the formulation are about 0.1 mm to about 3 mm in size.

28. The controlled release pharmaceutical pellet formulation of claim 19, wherein the pellet formulation further comprises one or more of microcrystalline cellulose, magnesium stearate, talc, or titanium dioxide.

29. A method of maintaining the remission of ulcerative colitis comprising, administering a controlled release pharmaceutical pellet formulation for the treatment of the intestinal tract, which controlled release pharmaceutical pellet formulation is as defined in claim 1.

30. The method of claim 29, wherein the pharmaceutically active compound comprises 5-aminosalicylic acid, balsalazide, sulfasalazine or a pharmaceutically acceptable salt thereof.

31. The method of claim 29, wherein the pharmaceutical pellet formulation is contained in capsules.

32. The method of claim 29, wherein the pharmaceutical pellet formulation is contained in sachets.

33. The method of claim 29, wherein the pharmaceutical pellet formulation is used for the prevention of, treatment of or the prevention of recurrence of inflammatory intestinal disorders, formation of polyps, intestinal cancer, colorectal polyps or colorectal cancer.

34. The method of claim 33, wherein the inflammatory intestinal disorders comprise Crohn's disease or ulcerative colitis.

35. The method of claim 29, wherein the pharmaceutical pellet formulation is used for the maintenance of remission of ulcerative colitis.

36. The method of claim 29, wherein the pellet formulation further comprises pharmaceutically tolerable additives.

37. The method of claim 29, wherein the pellets of the formulation are about 0.1 mm to about 3 mm in size.

38. The method of claim 29, wherein the pellet formulation further comprises one or more of microcrystalline cellulose, magnesium stearate, talc, or titanium dioxide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Queensland Health
Novartis
Fuji
Dow
Cerilliant
Julphar
McKesson
Chubb
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot